The 340B Drug Pricing Program, Hospital Prices, and Competition in Commercial Markets.

OBJECTIVE To examine whether hospital eligibility for the 340b drug pricing program reduces prices for clinician-administered drugs in commercial insurance markets and whether effects vary by market competition. STUDY SETTING AND DESIGN We conducted a quasi-experimental study using a regression discontinuity design that leverages the federal eligibility threshold for 340B participation (disproportionate share hospital [DSH] percentage > 11.75%). The study included non-profit and public acute care hospitals that billed for clinician-administered drugs in the outpatient setting between 2012 and 2014. The primary outcome was hospital-insurer negotiated unit prices for high-spending outpatient drugs. Secondary outcomes included drug volume and revenue. DATA SOURCES AND ANALYTIC SAMPLE We analyzed secondary data from the Health Care Cost Institute (HCCI), which includes claims from three national commercial insurers linked to hospital-level characteristics from the Hospital Cost Report Information System (HCRIS) and provider identifiers from the National Plan and Provider Enumeration System (NPPES). The analytic sample comprised 637 hospitals billing 148,037 clinician-administered drug claims for the five drugs with highest total spending. PRINCIPAL FINDINGS Hospital 340B eligibility was associated with a $605 reduction (95% CI: -934 to -276) in median unit drug prices, a 25% decrease relative to the mean price among ineligible hospitals at the threshold ($2387). Effects were concentrated in competitive markets (Herfindahl-Hirschman Index [HHI] ≤ 1800), where eligibility was associated with a $793 reduction (95% CI: -1197 to -388), a 32% decrease. In highly concentrated markets, effects were small and statistically insignificant. Price reductions were offset by non-significant increases in drug volume (25%) and neutral effects on drug revenue. CONCLUSIONS Hospital 340B eligibility reduced commercial drug prices only in competitive markets. These findings suggest that market competition is critical for ensuring that policy-driven hospital cost savings are shared with payers and patients.

• Publication year

  2026

• Venue

  Health Services Research

• Publication date

  2026-02-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1111/1475-6773.70085PMID 41621986PMCID PMC12861591
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Hospital Prices for Physician-Administered Drugs for Patients with Private Insurance.

  2024cited by this paper
• Reforming 340B to Serve the Interests of Patients, Not Institutions.

  2024cited by this paper
• The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program.

  2023cited by this paper
• Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics

  2022cited by this paper
• Trends in Prescription Drug Launch Prices, 2008-2021.

  2022cited by this paper
• Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?

  2021cited by this paper
• 340B Drug Pricing Program and hospital provision of uncompensated care.

  2021cited by this paper
• Sharing the Burden of Subsidization: Evidence on Pass-Through from a Subsidy Revision in Medicare Part D

  2021cited by this paper
• Relationship between initiation of 340B participation and hospital safety-net engagement.

  2020cited by this paper
• Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases

  2020cited by this paper
• Consequences of the 340B Drug Pricing Program

  2018cited by this paper
• Impact of the 340B Drug Pricing Program on Cancer Care Site and Spending in Medicare

  2018cited by this paper
• Do Larger Health Insurance Subsidies Benefit Patients or Producers? Evidence from Medicare Advantage.

  2018cited by this paper
• Evaluating The Role Of Payment Policy In Driving Vertical Integration In The Oncology Market.

  2017cited by this paper
• Market Share Matters: Evidence Of Insurer And Provider Bargaining Over Prices.

  2017cited by this paper
• Who benefits when the government pays more? Pass-through in the Medicare Advantage program

  2016cited by this paper
• Regression discontinuity designs in healthcare research

  2016cited by this paper
• The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

  2016cited by this paper
• THE PRICE AIN'T RIGHT? HOSPITAL PRICES AND HEALTH SPENDING ON THE PRIVATELY INSURED.

  2016cited by this paper
• A Practitioner’s Guide to Cluster-Robust Inference

  2015cited by this paper
• The Industrial Organization of Health Care Markets

  2015cited by this paper
• THE PRICE AIN ’ T RIGHT ? HOSPITAL PRICES AND HEALTH SPENDING ON THE PRIVATELY INSURED Zack

  2015cited by this paper
• The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.

  2014cited by this paper
• Saving babies? Revisiting the effect of very low birth weight classification.

  2011cited by this paper
• The increased concentration of health plan markets can benefit consumers through lower hospital prices.

  2011cited by this paper
• Hospital market concentration, pricing, and profitability in orthopedic surgery and interventional cardiology.

  2011cited by this paper
• Regression Discontinuity Designs in Economics

  2010cited by this paper
• Manipulation of the Running Variable in the Regression Discontinuity Design

  2005cited by this paper

• No citing papers are available for this paper.